Daniel Bagley, Colgate-Palmolive Company
Rodger Curren, Institute for In Vitro Sciences
G. Frank Gerberick, The Procter & Gamble Company
Thomas Hartung, Johns Hopkins University/ CAAT
Robert Landsiedel, BASF
Ann De Smedt, Johnson & Johnson
Institute for In Vitro Sciences, Inc.
The emergence of new national and international programs mandating increased toxicological safety testing of products and ingredients is a major driving force for the development of a “new toxicology.” From the REACH program in Europe to the reauthorization of the Toxic Substances Control Act (TSCA) in the US, new legislation is making faster, and more reliable testing methods essential. Non-animal, human focused, in vitro approaches are foreseen as the only realistic way to provide the required information. The National Academy of Sciences’ report: Toxicity Testing in the 21st Century: A Vision and Strategy, clearly outlines why scientists need to understand the availability and application of in vitro test methods.Join us for the 2010 In Vitro Alternatives Forum to learn about upcoming toxicity testing challenges and the current activities designed to meet them. In addition to presentations on a number of in vitro and in silico approaches, special emphasis will be placed on integrated testing strategies to identify skin sensitizers – an extremely important area of toxicity testing covered by the European Union’s 7th Amendment to the Cosmetics Directive.
This meeting will offer useful information including:
Registration fee inlcudes cocktail reception on day 1, breakfast and lunch on Day 2. It does not include travel or hotel accomodations. A limited number of rooms have been held at Hotel Monaco until September 24 for a rate of $209 per night (excluding tax). Use Group Code 701413 to make reservations at hotel.